Anti-Human IFN-β 0 BewertungenSubmit a Review Produktdetails Katalognummer: 500-P32B Beschreibung: Source: Polyclonal Rabbit Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IFN-beta. Anti-Human IFN-beta-specific antibody was purified by affinity chromatography employing immobilized Human IFN-beta matrix. Immunogen: E.coli derived Recombinant Human IFN-β (PeproTech catalog# 300-02B)* *Catalog# 300-02B has been replaced with 300-02BC. Sandwich ELISA: To detect Human IFN-β by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech’s Biotinylated Anti-Human IFN-β (500-P32BBt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human IFN-β. Western Blot: To detect Human IFN-β by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. When used in conjunction with compatible secondary reagents, the detection limit for recombinant Human IFN-β is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions. Note: Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information. crossreactivity: Human, Mouse References SDS Datenblattsuche Product Line Country Of Origin: USA Not for human use. Research Interest COVID-19 AIDS/HIV Cancer Immune System Neurobiology product.subtitle.recentcitations Erstautor Gozgit, J M Titel PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Literaturstelle Cancer Cell; 39(9) pg1214-1226.e10 PubMed ID 34375612 Erstautor Kölle, J Titel Respiratory infections regulated blood cells IFN-β-PD-L1 pathway in pediatric asthma. Literaturstelle Immunity, Inflammation and Disease; 8(3) pg310-319 PubMed ID 32394602 Erstautor Liu, Y Titel STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells. Literaturstelle The Journal of Clinical Investigation; 128(3) pg1057-1073 PubMed ID 29431732